WCLC 2025 - Posters & ePosters-P1.11.45 Real-World Prognosis of Non-Squamous NSCLC Patients With Liver, Bone, or Brain Metastases Treated With Frontline Therapies

P1.11.45 Real-World Prognosis of Non-Squamous NSCLC Patients With Liver, Bone, or Brain Metastases Treated With Frontline Therapies

Back to course

Pdf Summary

This real-world retrospective study from AbbVie analyzed outcomes in 1,968 adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab (pembro) monotherapy, chemotherapy (chemo), or pembrolizumab plus chemotherapy (pembro+chemo) from 2017 to June 2023. Data were derived from Optum’s Market Clarity database, focusing on patients with liver, bone, or brain metastases, which are common sites linked to poor prognosis in NSCLC.<br /><br />Key findings include:<br />- Patient median ages were 66 years for pembro+chemo and chemo groups, and 71 for pembro monotherapy.<br />- Bone metastases were found in 46%, brain metastases in 42%, and liver metastases in 17% of patients.<br />- Patients treated with pembro (with or without chemo) had higher rates of bone and liver metastases compared to those on chemo alone.<br />- PD-L1 expression was higher among pembro monotherapy patients (88% with PD-L1 ≥1%).<br />- Disease burden, defined by presence of brain, bone, and liver metastases, influenced survival outcomes. Patients without liver or bone metastases had longer median and 3-year overall survival (OS) across all treatments; brain metastases had a less pronounced negative impact.<br />- Median OS was shortest in patients with liver or bone metastases regardless of treatment. For example, median OS for liver metastases was approximately 6.8-7.6 months, compared to 13.8-17.7 months without.<br />- The addition of immunotherapy (pembro) to chemotherapy provided modest survival benefit, especially limited in patients with brain metastases, highlighting current unmet needs.<br /><br />The study concludes metastatic sites significantly affect prognosis and response to first-line therapies in metastatic NSCLC. While pembrolizumab-based regimens are standard, survival remains poor for patients with liver or bone metastases, underscoring the need for improved treatments tailored by metastatic site. Further research is needed to control for baseline differences and validate these findings. This data enhances understanding of metastatic NSCLC outcomes and therapy optimization.

Asset Subtitle

Mona Cai

Meta Tag

Speaker Mona Cai

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

metastatic non-small cell lung cancer

NSCLC

pembrolizumab monotherapy

chemotherapy

pembrolizumab plus chemotherapy

bone metastases

brain metastases

liver metastases

overall survival

PD-L1 expression